
The CLL Prognostication/Risk Stratification Gene Panel is a Next-Generation Sequencing (NGS)–based molecular test performed on EDTA whole blood samples. It analyzes key genes and mutations linked with the development and behavior of Chronic Lymphocytic Leukemia (CLL), a cancer of the blood and bone marrow that affects white blood cells.
CLL is a heterogeneous disease, meaning it behaves differently in every patient. Some cases progress slowly and require only monitoring, while others are more aggressive and need early intervention. This gene panel helps doctors assess an individual’s risk level and make informed clinical decisions.
The test evaluates mutations in important hotspot, full, and fusion genes associated with CLL and other hematological malignancies:
- Hotspot genes: ABL1, FLT3, JAK2, MYD88, SF3B1
- Full genes: SH2B3, TP53
- Gene fusions: FGFR1, FGFR2, PDGFRA, PDGFRB
By detecting these gene mutations, the test helps doctors stratify patients into risk categories (low, intermediate, or high risk) and decide on the most suitable treatment approach, whether active monitoring, targeted therapy, or clinical trial enrollment.
Doctors may recommend this test for individuals with newly diagnosed CLL, persistent or relapsed disease, or those who show clinical signs of disease progression such as rapid lymphocyte doubling, cytopenias, or organ enlargement.
For this test, it is important to submit the clinical history, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results.
The CLL Prognostication/Risk Stratification Gene Panel analyzes multiple genes in the blood that are linked to the development and progression of Chronic Lymphocytic Leukemia (CLL). It uses advanced PCR-based next-generation sequencing (NGS) to detect genetic mutations and variations that help predict how aggressive the disease might be and how it may respond to treatment.
This panel includes:
Hotspot genes (ABL1, FLT3, JAK2, MYD88, SF3B1): Common regions where mutations often occur in blood cancers.
Full genes (SH2B3, TP53): Entire genes analyzed to identify both common and rare mutations that influence prognosis and therapy response.
Gene fusions (FGFR1, FGFR2, PDGFRA, PDGFRB): Abnormal joining of genes that may drive cancer growth and affect targeted treatment choices.
By studying these genes, the test helps determine disease prognosis, identify high-risk patients, and guide doctors in planning personalized treatment strategies and follow-up care.
The CLL Prognostication/Risk Stratification Gene Panel test is done:
- To evaluate disease risk and prognosis in newly diagnosed CLL patients
- To guide treatment decisions and therapy selection
- To identify high-risk genetic mutations requiring closer monitoring or targeted therapy
- To assess disease relapse or progression
- To determine eligibility for clinical trials or new drug therapies
- Provide your clinical history, previous test reports, and a valid prescription. Tata 1mg consolidated TRF to be filled.





















